BIIB
Price
$138.74
Change
+$6.52 (+4.93%)
Updated
Sep 2, 04:31 PM (EDT)
Capitalization
19.39B
50 days until earnings call
OPK
Price
$1.38
Change
-$0.00 (-0.00%)
Updated
Sep 2, 04:31 PM (EDT)
Capitalization
1.1B
64 days until earnings call
Interact to see
Advertisement

BIIB vs OPK

Header iconBIIB vs OPK Comparison
Open Charts BIIB vs OPKBanner chart's image
Biogen
Price$138.74
Change+$6.52 (+4.93%)
Volume$508
Capitalization19.39B
OPKO Health
Price$1.38
Change-$0.00 (-0.00%)
Volume$2.93K
Capitalization1.1B
BIIB vs OPK Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 6.85B. The market cap for tickers in the group ranges from 658 to 186.06B. TMO holds the highest valuation in this group at 186.06B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 2%. For the same Theme, the average monthly price growth was 14%, and the average quarterly price growth was 42%. NBY experienced the highest price growth at 96%, while OTLK experienced the biggest fall at -68%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -7%. For the same stocks of the Theme, the average monthly volume growth was -38% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 54
SMR Rating: 87
Profit Risk Rating: 90
Seasonality Score: -26 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 10.24B. The market cap for tickers in the group ranges from 1.1B to 19.39B. BIIB holds the highest valuation in this group at 19.39B. The lowest valued company is OPK at 1.1B.

High and low price notable news

The average weekly price growth across all stocks in the group was -4%. For the same group, the average monthly price growth was 4%, and the average quarterly price growth was -13%. OPK experienced the highest price growth at -2%, while BIIB experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the group was -32%. For the same stocks of the group, the average monthly volume growth was -34% and the average quarterly volume growth was -72%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 72
P/E Growth Rating: 96
Price Growth Rating: 61
SMR Rating: 83
Profit Risk Rating: 100
Seasonality Score: 25 (-100 ... +100)
VS
BIIB vs. OPK commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and OPK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (BIIB: $132.22 vs. OPK: $1.38)
Brand notoriety: BIIB: Notable vs. OPK: Not notable
BIIB represents the Pharmaceuticals: Major, while OPK is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIIB: 79% vs. OPK: 64%
Market capitalization -- BIIB: $19.39B vs. OPK: $1.1B
BIIB [@Pharmaceuticals: Major] is valued at $19.39B. OPK’s [@Medical Specialties] market capitalization is $1.1B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.14B. The average market capitalization across the [@Medical Specialties] industry is $10.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileOPK’s FA Score has 0 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • OPK’s FA Score: 0 green, 5 red.
According to our system of comparison, OPK is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while OPK’s TA Score has 8 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 4 bearish.
  • OPK’s TA Score: 8 bullish, 1 bearish.
According to our system of comparison, OPK is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -5.09% price change this week, while OPK (@Medical Specialties) price change was -2.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.27%. For the same industry, the average monthly price growth was +2.61%, and the average quarterly price growth was +10.01%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.16%. For the same industry, the average monthly price growth was +9.68%, and the average quarterly price growth was +9.42%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

OPK is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.27% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Medical Specialties (+0.16% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($19.4B) has a higher market cap than OPK($1.1B). OPK YTD gains are higher at: -6.122 vs. BIIB (-13.536). BIIB has higher annual earnings (EBITDA): 2.79B vs. OPK (59.6M). BIIB has more cash in the bank: 2.76B vs. OPK (272M). OPK has less debt than BIIB: OPK (396M) vs BIIB (6.6B). BIIB has higher revenues than OPK: BIIB (10B) vs OPK (664M).
BIIBOPKBIIB / OPK
Capitalization19.4B1.1B1,772%
EBITDA2.79B59.6M4,688%
Gain YTD-13.536-6.122221%
P/E Ratio12.65N/A-
Revenue10B664M1,506%
Total Cash2.76B272M1,014%
Total Debt6.6B396M1,665%
FUNDAMENTALS RATINGS
BIIB vs OPK: Fundamental Ratings
BIIB
OPK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7394
PRICE GROWTH RATING
1..100
6161
P/E GROWTH RATING
1..100
9598
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OPK's Valuation (55) in the Biotechnology industry is somewhat better than the same rating for BIIB (89). This means that OPK’s stock grew somewhat faster than BIIB’s over the last 12 months.

OPK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that OPK’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (73) in the Biotechnology industry is in the same range as OPK (94). This means that BIIB’s stock grew similarly to OPK’s over the last 12 months.

BIIB's Price Growth Rating (61) in the Biotechnology industry is in the same range as OPK (61). This means that BIIB’s stock grew similarly to OPK’s over the last 12 months.

BIIB's P/E Growth Rating (95) in the Biotechnology industry is in the same range as OPK (98). This means that BIIB’s stock grew similarly to OPK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBOPK
RSI
ODDS (%)
N/A
Bullish Trend 5 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
58%
Bearish Trend 5 days ago
86%
Momentum
ODDS (%)
Bearish Trend 5 days ago
69%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bearish Trend 5 days ago
70%
Bullish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 5 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
57%
Bullish Trend 5 days ago
73%
Advances
ODDS (%)
Bullish Trend 12 days ago
53%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
69%
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
72%
Bullish Trend 5 days ago
74%
Aroon
ODDS (%)
Bullish Trend 5 days ago
57%
Bullish Trend 5 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GURCX32.100.21
+0.66%
NAA Risk Managed Real Estate C
DIFFX12.47-0.01
-0.08%
MFS Diversified Income R3
PEIZX24.54-0.06
-0.24%
PGIM Jennison Value Z
RYGRX93.47-1.01
-1.07%
Rydex S&P 500 Pure Growth C
LGLQX51.75-0.70
-1.33%
Lord Abbett Growth Leaders R2

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.32%
PFE - BIIB
56%
Loosely correlated
+0.65%
AMGN - BIIB
49%
Loosely correlated
+0.74%
MRK - BIIB
49%
Loosely correlated
+1.09%
NVS - BIIB
46%
Loosely correlated
+0.06%
GSK - BIIB
46%
Loosely correlated
+0.58%
More

OPK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OPK
1D Price
Change %
OPK100%
-2.82%
ICUI - OPK
41%
Loosely correlated
+0.49%
CLPT - OPK
39%
Loosely correlated
N/A
UTMD - OPK
36%
Loosely correlated
+0.24%
XAIR - OPK
35%
Loosely correlated
+1.83%
NOTV - OPK
34%
Loosely correlated
+0.60%
More